What is adjuvant trastuzumab?
Trastuzumab, a monoclonal antibody directed against the extracellular domain of HER-2, improves survival and quality of life in women with HER-2-positive metastatic breast cancer receiving chemotherapy.
What is trastuzumab pertuzumab based therapy?
Perjeta (chemical name: pertuzumab) used in combination with Herceptin (chemical name: trastuzumab), another targeted therapy medicine, and Taxotere (chemical name: docetaxel), a type of chemotherapy, to treat HER2-positive, metastatic breast cancer that hasn’t been treated with either Herceptin or chemotherapy yet.
Is trastuzumab immunotherapy or targeted therapy?
Targeted therapy drugs attack specific targets inside cancer cells. The drugs that are currently available do not work for all types of breast cancer. They are useful only for HER2 positive breast cancers. For early or locally advanced breast cancer, the main targeted therapy drug is trastuzumab (brand name Herceptin).
Which toxicity is associated with pertuzumab and trastuzumab?
Trastuzumab plus pertuzumab may have clinical benefit in selected patients who have been previously treated with trastuzumab. Cardiac toxicity, although asymptomatic in most cases, was associated with this treatment.
What type of therapy is pertuzumab?
Pertuzumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Trastuzumab is a form of “targeted therapy” because it works by attaching itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors.
What are the side effects of pertuzumab?
Common side effects of pertuzumab and trastuzumab
- Risk of infection. This treatment can reduce the number of white blood cells in your blood.
- Bruising and bleeding.
- Anaemia (low number of red blood cells)
- Effects on the heart.
- Diarrhoea.
- Feeling sick.
- Loss of appetite.
- Sore mouth.
Is it safe to take pertuzumab with trastuzumab?
In this trial, we investigated whether pertuzumab, when added to adjuvant trastuzumab and chemotherapy, improves outcomes among patients with HER2-positive early breast cancer.
When to use pertuzumab in combination with Herceptin?
PERJETA ® (pertuzumab) is indicated for use in combination with Herceptin ® (trastuzumab) and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
Where can I get neoadjuvant pertuzumab for cancer?
11University Hospital Erlangen, Department of Obstetrics and Gynecology, Friedrich-Alexander-Universität Erlangen, Comprehensive Cancer Center Erlangen-Europäische Metropolregion Nuremberg, Erlangen, Germany. 12Translational Research in Oncology, Biopark, Paris, France.
Is there a safety trial for neoadjuvant trastuzumab?
Safety was analysed in patients who received at least one dose of study medication. This trial is registered with ClinicalTrials.gov, number NCT02131064, and follow-up of the adjuvant phase is ongoing.
